CD49b (ITGA2) human monoclonal antibody, clone F2H11
Applications | ELISA, FC, IF |
Reactivities | Human |
Conjugation | Unconjugated |
CD49b (ITGA2) human monoclonal antibody, clone F2H11
Applications | ELISA, FC, IF |
Reactivities | Human |
Conjugation | Unconjugated |
CD49b (ITGA2) human monoclonal antibody, clone B4F12
Applications | ELISA, FC, IF |
Reactivities | Human |
Conjugation | Unconjugated |
CD38 monoclonal antibody (daratumumab biosimilar)
Applications | ELISA, FC |
Reactivities | Human |
Conjugation | Unconjugated |
CD70 monoclonal antibody (vorsetuzumab biosimilar)
Applications | ELISA, FC |
Reactivities | Human |
Conjugation | Unconjugated |
SARS-CoV-2 monoclonal antibody (CB6 biosimilar)
Applications | ELISA, FC |
Reactivities | SARS-CoV-2 |
Conjugation | Unconjugated |
SARS-CoV monoclonal antibody (CR3022 biosimilar)
Applications | ELISA, FC |
Reactivities | SARS-CoV-2 |
Conjugation | Unconjugated |
Recombinant Anti-erbB-2 (Her-2/neu) (Clone 4D5-8 (trastuzumab))
Applications | ELISA, FC, IHC |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD52 (Clone Campath-1H)
Applications | ELISA, FC, IHC, WB |
Reactivities | Human, Monkey |
Conjugation | Unconjugated |
Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-TNF alpha (Clone cA2 (Infliximab))
Applications | ELISA, FC |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TRP-1, gp75 (Clone TA99)
Applications | ELISA, FC, IF, IHC, IP, WB |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Human Ephrin Type A receptor 2 (Clone 1C1)
Applications | ELISA, FC, IF, WB |
Reactivities | Human |
Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-TNF alpha (Clone CDP 571 (Humicade))
Applications | ELISA |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
USD 523.00
2 Weeks
Recombinant Anti-alpha 5 beta 1 Integrin (Clone M200 (Volociximab))
Applications | ELISA, FC, IF, IHC |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD4 (Clone CE9.1 (Clenoliximab))
Applications | ELISA, FC, IHC |
Reactivities | Chimpanzee, Human |
Conjugation | Unconjugated |
Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-alpha-gal epitope (Clone m86)
Applications | ELISA, FC |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-EGFR (Clone Matuzumab)
Applications | ELISA, FC, IF, WB |
Reactivities | Human |
Conjugation | Unconjugated |
Recombinant Anti-ED-B domain of fibronectin (Clone A2)
Applications | ELISA, IHC, WB |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-ED-B domain of fibronectin (Clone G4)
Applications | ELISA, IHC, WB |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Bet v 1 (Clone M0418)
Applications | ELISA |
Conjugation | Unconjugated |
Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Phl p 1 (Clone Clone 25)
Applications | ELISA, WB |
Reactivities | Rat |
Conjugation | Unconjugated |
Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-VEGF (Clone Bevacizumab)
Applications | ELISA, FC, IP, WB |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-TNF alpha (Clone D2E7 (Adalimumab))
Applications | ELISA, IF, IHC |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-RSV (Clone RSHZ19 (Felvizumab))
Applications | ELISA |
Reactivities | Respiratory Syncytial Virus |
Conjugation | Unconjugated |
Recombinant Anti-CD80 (Clone IDEC-114 (Galiximab))
Applications | ELISA, FC, IHC, IP, WB |
Reactivities | Human |
Conjugation | Unconjugated |
Recombinant Anti-IL-6 receptor (Clone rhPM-1 (Tocilizumab))
Applications | ELISA |
Reactivities | Human |
Conjugation | Unconjugated |
Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-GM2 ganglioside (Clone L55-81)
Applications | ELISA, IHC |
Reactivities | Human |
Conjugation | Unconjugated |
Recombinant Anti-CD40 (Clone 5D12)
Applications | ELISA, FC, IHC, IP |
Reactivities | Human, Monkey, Cynomolgus |
Conjugation | Unconjugated |
Recombinant Anti-Fas (Clone R-125224)
Applications | ELISA, FC |
Reactivities | Human |
Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-EGFR (Clone 2F8 (Zalutumumab; HuMax-EGFR))
Applications | ELISA, FC, WB |
Reactivities | Human |
Conjugation | Unconjugated |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
Applications | ELISA, IF |
Conjugation | Unconjugated |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
Applications | ELISA, IF |
Conjugation | Unconjugated |
Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
Applications | ELISA, IF |
Conjugation | Unconjugated |
Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD80 (Clone 16C10)
Applications | ELISA |
Reactivities | Human |
Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
Applications | ELISA, IF |
Reactivities | SARS-CoV |
Conjugation | Unconjugated |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
Applications | ELISA, IF |
Reactivities | SARS-CoV |
Conjugation | Unconjugated |
Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
Applications | ELISA, IF |
Reactivities | SARS-CoV |
Conjugation | Unconjugated |
Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
Applications | ELISA, IF |
Reactivities | SARS-CoV |
Conjugation | Unconjugated |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
Applications | ELISA, IF |
Reactivities | SARS-CoV |
Conjugation | Unconjugated |
Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
Applications | ELISA, IF |
Reactivities | SARS-CoV |
Conjugation | Unconjugated |
Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#14)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#14)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#14)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#16)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#16)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#16)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#42)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#42)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#42)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#45)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#45)
Applications | ELISA, Inhib |
Conjugation | Unconjugated |
Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |